PTC Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $213,172 | $196,786 | $186,704 | $210,118 |
Gross Profit | 196,889 | 185,938 | 168,312 | 143,848 |
EBITDA | -46,875 | -54,510 | -35,225 | 11,533 |
EBIT | -53,639 | -60,996 | -42,243 | -43,862 |
Net Income | -65,886 | -106,654 | -99,179 | -91,576 |
Net Change In Cash | 213,172 | 196,786 | 186,704 | 210,118 |
Free Cash Flow | -36,501 | -22,751 | -64,078 | 6,410 |
Cash | 779,709 | 526,001 | 654,779 | 548,355 |
Basic Shares | 76,845 | 76,925 | 76,725 | 76,496 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $806,780 | $937,822 | $698,801 | $538,593 |
Gross Profit | 806,780 | 872,336 | 654,123 | 506,265 |
EBITDA | -120,463 | -330,340 | -367,780 | -374,443 |
EBIT | -196,126 | -566,930 | -496,616 | -445,963 |
Net Income | -363,295 | -626,604 | -559,017 | -523,901 |
Net Change In Cash | 806,780 | 937,822 | 698,801 | 538,593 |
Cost of Revenue | 101,479 | -11,273 | ||
Free Cash Flow | -114,190 | -279,037 | -509,114 | -336,663 |
Cash | 779,709 | 594,001 | 410,705 | 773,376 |
Basic Shares | 76,845 | 74,838 | 71,728 | 70,466 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.34 |
2024-09-30 | -$1.39 |
2024-06-30 | -$1.27 |
2024-03-31 | -$1.20 |
